Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Alternative

<< Previous

Bullboard Posts

Next >>

Comment by PlaySafeon Aug 13, 2021 10:55am

117 Views

Post# 33700496

RE:RE:RE:Alternative

Agree, but you also have to think about what would have happened if they had gone into a Phase 3 (24 week GI safety and 12 week efficacy) trials at 200mg. If they can prove efficacy at 75mg or some lower dose then the Phase 3 - 24 week GI safety and 12 week efficacy have a much better chance at success at the lower dose based on what we know now from the AME study. In other words, I would rather wait another year for a successful Phase 3 trail then risk an almost certain failed Phase 3 trial at the higher dose.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity